On July 6, GenScript Biotech rose 5.07% in regular trading, trading at HK$14.44/share, with turnover of approximately HK$117 million. The rally was driven by sustained market enthusiasm for the AI-powered drug discovery sector, with GenScript positioned as a foundational infrastructure service provider in the AI drug discovery value chain.

On the news front, market attention toward AI drug discovery has continued to intensify in recent days. As a gene synthesis and life sciences tools platform company, GenScript has attracted capital inflows due to its role in providing wet-lab experimental services essential to AI-designed molecule validation. Reports indicate that ByteDance's AI drug discovery entity, AnewTherapeutics, has registered in Singapore, further boosting expectations for an explosion in demand for wet-lab experiment services supporting AI-driven drug development.

Within the Life Sciences Tools and Services sector, other stocks also showed positive movement, with Wuxi XDC up 4.13%, XtalPi up 4.05%, Wuxi Biologics up 2.18%, Insilico Medicine up 1.61%, and Wuxi AppTec up 1.41%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)